A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

• Status: Completed
• Trial end date: 2007-01-05
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant; Rifampin

Criteria

Inclusion criteria:

• healthy

• female subjects who cannot become pregnant

• able to swallow and keep down oral medication

• can understand and follow the protocol requirements and instructions

Exclusion criteria:

• smokes at least 4 packs per day in the past 12 months

• use of prescription or non-prescription drug(s)

• herbal or dietary supplements or vitamins with 14 days prior to first dose of study medication

• a clinically relevant abnormality medical condition or circumstance making the subject unsuitable for the study per the study doctor

• blood donation in excess of 1 pint within 56 days before dosing of medication

• iron deficient

• history or drug allergy of study medication

• history of drug or alcohol abuse or dependency within the past 6 months

• subjects cannot use any nicotine-containing products within the last 6 months

• positive for HIV, Hepatitis B or C

• active peptic ulcer disease

• uncontrolled nausea and vomiting

• active infection

• heart failure

• female who is lactating

• female who has a positive pregnancy test